In locally advanced and metastatic GC/GEJC, although monotherapy IO has demonstrated benefit in the subset of patients with mismatch-repair/microsatellite instability high (MMR/MSI-H) as well as in in the 3rd line setting in patients with high programmed death ligand-1 (PD-L1) expression, benefit is largely limited in the rest of the population [2, 3]. This evidence concerns the gene CD274 and gastric cancer.